54
Participants
Start Date
May 30, 2024
Primary Completion Date
June 30, 2026
Study Completion Date
August 31, 2026
CNP-106
CNP-106 is comprised of an antigenic AChR Peptide Pool (\~1 μg of each AChRα and AChRε peptide comprising AChR Peptide Pool Drug Substance per mg particles) dispersed within a negatively charged (-30 to -60 mV) polymer matrix of PLGA (Poly (DL-lactide-co-glycolide, 50:50 acid-end group)) particles (400-800 nm in size).
Placebo
CNP-106 Placebo
NOT_YET_RECRUITING
Virginia Commonwealth University, Richmond
NOT_YET_RECRUITING
Medical University of South Carolina, Charleston
RECRUITING
Atlantis Research, Miami
RECRUITING
Quantix Research, LLC, Miami
RECRUITING
University of South Florida, Tampa
NOT_YET_RECRUITING
Ohio State University Wexner Medical Center, Colombus
RECRUITING
Insight Research Institute, Dearborn, Dearborn
RECRUITING
Insight Hospital and Medical Center, Chicago
RECRUITING
University of Missouri, NextGen Precision Health, Columbia
NOT_YET_RECRUITING
University of Kansas Medical Center, Kansas City
RECRUITING
Nerve and Muscle Center of Texas, Houston
RECRUITING
Prolato Clinical Research Center, Houston
RECRUITING
Barrow Neurological Institute, Phoenix
NOT_YET_RECRUITING
Neuromuscular Clinic and Research Center, Phoenix
RECRUITING
Infusion for Health, Brea
RECRUITING
University of California, Irvine, Orange
RECRUITING
Yale University, New Haven
Lead Sponsor
COUR Pharmaceutical Development Company, Inc.
INDUSTRY